CD8A and ovarian cancer: A high ratio of PD-1+ TIM-3+ CD8 TILs in ovarian cancer was often observed in advanced stages and was associated with a high risk of recurrence, so immunotherapy to free these exhausted cells from impaired cytotoxicity is needed [36].